Abstract
In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Within different patient cohorts, application of cholecalciferol or ergocalciferol (native vitamin D) as well as calcifediol can help replenish vitamin D levels in patients with and without renal disease. However, it is unclear if such an approach is effective in modifying relevant clinical end-points. Currently available data are insufficient to clearly define situations in which calcifediol therapy might be superior to ergocalciferol or cholecalciferol therapy in terms of increasing calcidiol levels in CKD / ESRD. Similar to ergocalciferol or cholecalciferol application, also calcifediol therapy needs to undergo testing in randomized, controlled trials (RCT) in severe CKD or ESRD with reasonable end-points before recommendations about therapy can be established.
Keywords: Calcidiol, calcifediol, cholecalciferol, CKD-MBD, hyperparathyroidism, parathyroid hormone, vitamin D.
Current Vascular Pharmacology
Title:Calcifediol – More than the Stepchild of CKD-MBD Therapy?
Volume: 12 Issue: 2
Author(s): Vincent M. Brandenburg and Thilo Kruger
Affiliation:
Keywords: Calcidiol, calcifediol, cholecalciferol, CKD-MBD, hyperparathyroidism, parathyroid hormone, vitamin D.
Abstract: In patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), 25OH-vitamin D (calcidiol) deficiency or insufficiency is a common finding with high prevalence. Numerous epidemiological studies have found an independent association of low levels of calcidiol with increased morbidity and mortality. Within different patient cohorts, application of cholecalciferol or ergocalciferol (native vitamin D) as well as calcifediol can help replenish vitamin D levels in patients with and without renal disease. However, it is unclear if such an approach is effective in modifying relevant clinical end-points. Currently available data are insufficient to clearly define situations in which calcifediol therapy might be superior to ergocalciferol or cholecalciferol therapy in terms of increasing calcidiol levels in CKD / ESRD. Similar to ergocalciferol or cholecalciferol application, also calcifediol therapy needs to undergo testing in randomized, controlled trials (RCT) in severe CKD or ESRD with reasonable end-points before recommendations about therapy can be established.
Export Options
About this article
Cite this article as:
Brandenburg M. Vincent and Kruger Thilo, Calcifediol – More than the Stepchild of CKD-MBD Therapy?, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990027
DOI https://dx.doi.org/10.2174/15701611113119990027 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Evaluation of Gamma Amino Butyric Acid (GABA) and Glibenclamide Combination Therapy in Streptozotocin Induced Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Direct Renin Inhibitor, Aliskiren, on Arterial Hypertension, Chronic Kidney Disease and Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Radioprotective Effect of Febuxostat Against Testicular Damage Induced by Ionizing Radiation in Mice
Current Radiopharmaceuticals Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Current Diabetes Reviews Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy The Vascular Wall and the Haemostatic Balance in Type 1 Diabetic Patients with Nephropathy
Vascular Disease Prevention (Discontinued) Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Advances in the Methodologies for the Analysis of Acute Kidney Injury Biomarkers
Recent Patents on Biomarkers Therapeutic Use of Calcitriol
Current Vascular Pharmacology MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews